The purpose of this paper is to evaluate the effectiveness (through the analytic prism of “corporate citizenship”) of the US pharmaceutical industry's political strategy behind the Partnership for Prescription Assistance, the program that the industry has recently initiated to address the prescription drug needs of senior and other low‐income American citizens.
By reviewing data collected by PhRMA, the industry's association, over a one‐year period, the Partnership for Prescription Assistance program is evaluated for: performance (over periods of one month, three months, six months and one year); congruence with the concept of corporate citizenship; and effectiveness as an industry political strategy.
During its first year of operation, the Partnership for Prescription Assistance has matched two million Americans with public and private assistance programs that meet their prescription health needs. Furthermore, the Partnership for Prescription Assistance fits into the corporate citizenship perspective, and offers the pharmaceutical industry a viable alternative (“industry political strategy”) to state and federal legislative efforts to establish prescription drug importation programs.
This article addresses recent efforts (in the form of the Partnership for Prescription Assistance) by the US pharmaceutical industry to counteract proposed legislation to allow prescription drug importation in the USA. The article provides evidence of industry political strategy success in the implementation of the Partnership for Prescription Assistance. This article will have value to pharmaceutical industry management, health care advocates, public policy makers, and business faculty whose research interest lies in the area of business and society.
